Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfusion risks and limitations.

F Mercuriali1, G Inghilleri

  • 1Servizio di Immunoematologia e Trasfusionale, Istituto Ortopedico G. Pini, Milano.

Minerva Anestesiologica
|July 2, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survey on the usage of therapeutic erythrocytapheresis in transfusion services in Italy for the treatment of polycythemia vera, secondary erythrocytosis and hemochromatosis.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2023
Same author

Indications for autotransfusion in surgical oncology.

Tumori·2001
Same author

New approach to preoperative autologous blood donation (PABD)

The International journal of artificial organs·2000
Same author

Management of preoperative anaemia.

British journal of anaesthesia·1999
Same author

[Blood transfusion in oncologic surgery: the role of recombinant human erythropoietin (rHuEPO)].

Tumori·1999
Same author

Epoetin alfa in low hematocrit patients to facilitate autologous blood donation in total hip replacement: a randomized, double-blind, placebo-controlled, dose-ranging study.

Acta haematologica·1998
Same journal

Rectus sheath block for analgesia in open abdominal surgery: a systematic review, meta-analysis and trial sequential analysis.

Minerva anestesiologica·2026
Same journal

Highlights from the June 2026 issue.

Minerva anestesiologica·2026
Same journal

Validation of the Gendolcat model for chronic postsurgical pain after cesarean section: a multicenter study.

Minerva anestesiologica·2026
Same journal

Dual block strategy for complex incision in pediatric kidney transplantation: M-TAPA and quadroiliac plane block combination.

Minerva anestesiologica·2026
Same journal

Technical note: a novel fully visualized, glottic-sparing strategy for infant one-lung ventilation.

Minerva anestesiologica·2026
Same journal

Ultrasound-guided recto-intercostal fascial plane block facilitating early extubation following pediatric subxiphoid pericardial window surgery.

Minerva anestesiologica·2026
See all related articles

Blood transfusions are safer but still carry risks like infections and immune reactions. Bacterial contamination and acute hemolytic reactions remain key safety concerns for patients.

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Patient Safety

Background:

  • Blood transfusion safety has improved due to better screening and testing.
  • Despite advancements, transfusion therapy is not entirely risk-free.
  • Key risks include infectious, immunologic, and non-infectious hazards.

Purpose of the Study:

  • To review the residual risks associated with blood transfusion therapy.
  • To highlight current safety concerns in transfusion medicine.

Main Methods:

  • Review of current literature on blood transfusion safety.
  • Analysis of infectious, immunologic, and non-infectious transfusion hazards.

Main Results:

  • Viral transmission risk is low, but bacterial contamination is a growing concern.

Related Experiment Videos

  • Immunologic risks include alloimmunization, febrile reactions, and acute hemolytic reactions, a leading cause of transfusion-related death.
  • Transfusion can also cause immunosuppression and non-infectious complications like pulmonary edema.

    • Conclusions:

    • While significantly safer, blood transfusion therapy still presents residual risks.
    • Ongoing vigilance is necessary to mitigate infectious and immunologic complications, particularly bacterial contamination and hemolytic reactions.